Sponsors (5)
Introduced August 12, 2025 by Frank Pallone · Last progress August 12, 2025
The bill strengthens consumer protection and transparency around GRAS food substances and modernizes FDA review processes, but it does so by imposing higher data, fee, and compliance burdens that may raise costs, delay market entry, and disrupt some products—especially affecting small producers and consumer prices.
All consumers face stronger protections because GRAS decisions will require qualified scientific consensus, more safety data, and periodic reassessments that reduce the risk of unsafe food substances.
Consumers and the public gain greater transparency because FDA must post GRAS notices, supporting data, written determinations, and revocations and open a 60‑day public comment period.
Manufacturers and petitioners receive clearer regulatory standards and definitions (e.g., carcinogenicity, reproductive toxicity, food‑contact substances) and an explicit FDA 'not to object' pathway, which improves legal/regulatory certainty for companies that meet the standards.
Small food manufacturers and petitioners will face substantially higher compliance costs to assemble expert reviews, expanded safety data, repeated reassessments, and new fees.
Higher user fees and compliance costs are likely to be passed to consumers or deter small innovators, raising food prices and slowing introduction of new ingredients or products.
Reliance on FDA review timelines (a 180‑day review plus possible 90‑day extension) and expanded review requirements can delay market entry for new ingredients and product launches.
Based on analysis of 6 sections of legislative text.
Sets a stricter statutory GRAS standard, creates mandatory FDA GRAS notices and 3‑year reassessments, and expands FDA fee authority to cover review costs.
Rewrites how substances used in food are treated as "generally recognized as safe" (GRAS), creates a mandatory FDA notification and review process for new GRAS uses, and requires the FDA to reassess safety of groups of substances on a regular schedule. It also defines key terms, increases data and transparency requirements, allows the FDA to revoke prior no‑objection letters, and expands fee authority so the agency can recover the costs of reviews and reassessments.